Nanostics in the Media

ARTICLE - 15.10.2021

Nanostics Welcomes New Board Member Mike Schoenberger

Nanostics is EXCITED to announce Mike Schoenberger as its newest Board Member! We also send a huge THANK YOU to outgoing board member Dale Klein for his dedicated service.

Full Article

ARTICLE - 16.06.2020

Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site

PR: Nanostics announced the re-opening of their clinical validation study testing ClarityDX Prostate in a real-world setting. The study is also greatly benefiting from further expansion into the US with the addition of a new patient recruitment site at an award-winning United States clinical research institution.

Full Article

ARTICLE - 21.04.2020

Nanostics is Developing and Validating a Simple Blood Test to Predict Severity of COVID-19 Disease in SARS-CoV-2 Positive Patients

PR today: Nanostics to use ClarityDX platform to develop & validate a blood test to predict COVID-19 severity in SARS-CoV-2 patients; with Canadian BioSample Repository in Alberta and Century Clinical Research Institute in Florida. “We’re joining the fight against COVID-19 by using our ClarityDX technology to rapidly and accurately predict which COVID-19 patients are at risk for developing severe disease” said John Lewis, CEO of Nanostics.

Full Article

ARTICLE - 29.01.2020

Alberta Impact with Bryce Lambert, Episode 3, 'Future of Health' DynaLIFE Accelerator Lab; benefits of this amazing Medical Lab program

Your technology’s proven in an academic lab⎯now you want it adopted into the healthcare system. The DynaLIFE Accelerator helps startups develop and validate tests in a real-world setting.

Full Article

ARTICLE - 15.01.2020

Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ID: NCT03957252

Clinical study to validate ClarityDX Prostate as a reflex test to high PSA levels to refine prediction of clinically significant prostate cancer has begun in a prospective cohort of 2800 men.

Full Article

ARTICLE - 12.01.2020

CBC News-Biotech firm recruiting Yukon men for trial, Prostate cancer group says it could save lives

Alberta-based Nanostics is hoping to recruit 200 Yukoners to the clinical validation study testing ClarityDX Prostate in a real-world setting.

Full Article

ARTICLE - 09.01.2020

CKRW 96.1 FM Radio-Cancer Study Comes to the Yukon

The Yukon Ride for Dad, which raises money for prostate cancer awareness and research, is making a substantial investment in Nanostic's research into diagnostic testing for prostate cancer.

Full Article

ARTICLE - 03.12.2019

Movember and Alberta Cancer Foundation campaigns boost prostate cancer screening study

News Medical Lifesciences - ClarityDX Prostate cancer diagnostic test validation study gets a boost in recruitment thanks to concurrent fundraising campaigns.

Full Article

ARTICLE - 08.10.2019

ClarityDX Prostate clinical validation study is expanding into the US with Century Clinical Research, Inc.

The Nanostics & APCaRI co-sponsored ClarityDX Prostate clinical validation study is expanding into the US by opening the Daytona Beach, Florida Century Clinical Research, Inc. recruitment site.

Full Article

ARTICLE - 03.10.2019

Nanostics featured on Alberta Impact Episode 5 with Bryce Lambert

1 of 7 Canadian men is diagnosed with prostate cancer each year. We cannot emphasize enough on how important it is to get tested each year. Nanostics has come up with a non-invasive diagnostic test to bring clarity to healthcare decisions. Their core technology is in development to be able to diagnose prostate cancer from a simple blood test.

Full Article

ARTICLE - 27.09.2019

The Cancer Consortium-Nanostics: Advanced Machine Learning to Detect Prostate Cancer

Nanostics' core technology, ClarityDX, combines a sensitive extracellular vesicle detection platform with advanced machine learning to diagnose a disease from a simple blood test.

Full Article

ARTICLE - 27.06.2019

Prostate Cancer News Today: Nanostics Launches Pivotal Study to Validate ClarityDX Prostate Diagnostic Test.

Ana Pena wrote for the Prostate Cancer News Today: The company says the diagnostic tool has the potential to spare many men unnecessary biopsies and treatments.

Full Article

ARTICLE - 04.06.2019

Faculty of Medicine & Dentistry: U of A spin-off company Nanostics launches clinical validation study for ClarityDX Prostate

NEWS STAFF REPORT: Blood test predicts aggressive prostate cancer with greater accuracy and less patient discomfort.

Full Article

ARTICLE - 27.05.2019

Nanostics and DynaLIFE productive partnership - video interview with Edmonton Journal

CSO Desmond Pink discusses Nanostics' productive partnership with DynaLIFE Medical labs’ Translational Research Program- a key relationship to bring ClarityDX to market.

Full Article

ARTICLE - 06.05.2019

Nanostics highlighted as a company developing better tests in En Route magazine article

Flying with @AirCanada? Pick up En Route magazine and read "19 Canadian Start-ups That Are Out to Change the World." Written by Danielle Groen and illustrated by Martina Paukova.

Full Article

ARTICLE - 07.01.2019

ClarityDX Prostate is one of five top picks for mind-blowing technologies and treatments in 2018

Global Edmonton Health reporter Su-Ling Goh highlighted 5 amazing medical technologies and treatments from Edmonton research teams and ClarityDX Prostate was one of them!

Full Article

ARTICLE - 26.10.2018

Edmonton Journal - New lab brings fledgling health tech companies together in shared space

A local startup with plans to market a more accurate prostate cancer screening test is one of the first businesses to set up shop in a new downtown shared lab space for health tech companies.

Full Article

ARTICLE - 26.07.2018

A Less Invasive Route to Test For Prostate Cancer

Alberta scientists, at Nanostics, have created a blood test that could make a significant impact in the way patients are tested and treated for prostate cancer.

Full Article

ARTICLE - 28.05.2018

Funding to develop technology that will detect prostate cancer earlier

EDMONTON — Alberta Innovates, the Alberta Cancer Foundation and DynaLIFE have joined together to help commercialize Alberta-owned innovations...

Full Article

ARTICLE - 20.09.2017

NVIDIA - How GPU-Powered Cellular Analysis Could Help Avoid Unnecessary Prostate Cancer Biopsies

1.3M North American men get biopsies each year checking for prostate cancer, many of them unnecessary. UofA researchers want to change that with a new test that relies on GPU computing.

Full Article

ARTICLE - 26.06.2017

Startup Nanostics preparing launch of blood-based biomarker test for prostate cancer

A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer.

Full Article

ARTICLE - 14.06.2017

New blood test uses nanotechnology to predict prostate cancer

A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer.

Full Article

ARTICLE - 06.06.2017

U of A uses nanotechnology to develop new test for aggressive prostate cancer

Alberta men diagnosed with prostate cancer could soon have a better blood test to help determine if they can bypass a painful and invasive biopsy.

Full Article

ARTICLE - 22.05.2017

Could there soon be a better way to protect against prostate cancer?

The PSA test for prostate cancer has been linked to unnecessary treatments and biopsies. That’s prompted researchers to start developing a more accurate prostate cancer detection tool.

Full Article

Publications/Webinars/White Papers

Publication Date: 16.10.2020

BMJ Open Cohort Profile Article: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada

The APCaRI Registry and Biorepository, established in 2014, facilitates the collection of clinical and patient-reported data plus biospecimens, to measure prostate cancer outcomes and support the development and clinical translation of innovative technologies. The ultimate goal is to better diagnose and predict outcomes for patients with prostate cancer.

Full Article

Author: Catalina Vasquez, Michael Kolinsky, Rume Djebah, Maxwell Uhlich, Bryan Donnelly, Adrian S Fairey, Eric Hyndman, Nawaid Usmani, Jackson Wu, Peter Venner, Dean Ruether, Gerald Todd, Michael Chetner, R Trafford Crump, Perrin H Beatty, John D Lewis
Publication Date: 06.07.2020

White Paper: Performance Qualification for MicroFlow Cytometers: Understanding technical limitations to improve your research

As microflow cytometry matures toward clinical applications for extracellular vesicle (EV) analysis, a concerted effort to improve reproducibility has begun. The new MISEV and MISEV MISEV-Flow guidelines are critical to enabling this reproducibility.

Full Article

Author: Desmond Pink, Michael Wong, Diana Pham, Renjith Pillai, Leanne Stifanyk, Sylvia Koch, Rebecca Hiebert, Oliver Kenyon, and John Lewis
Publication Date: 06.11.2019

Cowpea mosaic virus nanoparticles for cancer imaging and therapy

Nanoparticle platforms are attractive for theranostic applications due to their multifunctionality and multivalency. Some of the most promising nano-scale scaffolds have been co-opted from nature, such as the cowpea mosaic virus (CPMV). What makes CPMV so promising? They are non-infectious and nontoxic to humans and safe for use in intravital imaging and drug delivery. Click on the link to read more.

Full Article

Author: Perrin Beatty and John Lewis
Publication Date: 22.05.2019

PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks

We are pleased to present PROSPeCT, a user-friendly online clinical information system that offers an efficient way to query APCaRIs ( robust and expanding patient database to generate relevant and accurate results. Read the details in our article published in the Journal of Clinical Oncology - Clinical Cancer Informatics. Thank you to the Alberta Cancer Foundation and many others for their support.

Full Article

Publication Date: 04.10.2018

Intravital imaging tumor screen used to identify novel metastasis-blocking therapeutic targets

This is a micro-review of an original research article from the Lewis research group that identified multiple novel metastasis-blocking targets, by using a whole genome screen and intravital imaging approach, that could be used as therapeutic targets to inhibit solid tumour cell motility.

Full Article

Author: Konstantin Stoletov, Lian Willetts, Perrin H. Beatty, and John D. Lewis

Our Achievements

ARTICLE - 24.09.2018

BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2018 Awards Gala

CALGARY, Alberta — At its 2018 awards gala, BioAlberta, the province’s life sciences industry association, recognized two leaders for their innovation and achievements. BioAlberta congratulates Circle Cardiovascular Imaging Inc. for winning its Company of the Year award and Dr. John Lewis for winning its Scientific Achievement and Innovation Award.

Full Article

ARTICLE - 29.08.2018


Dr. John Lewis is the winner of the University of Alberta-TEC Edmonton Falling Walls Venture Competition which earned him entrance to the Falling Walls Finale Competition (the International Conference on Future Breakthroughs in Science and Society) which will be held in Berlin this November. Some travel expenses will be paid for.

Full Article